HUNTSVILLE, Ala. and KASSEL, Germany, May 20, 2026
Discovery Life Sciences has launched Luminos® Comprehensive, a next-generation IVDR-compliant clinical genomics platform designed to accelerate oncology trial enrollment and precision medicine workflows across Europe. The newly introduced 164-gene pan-tumor comprehensive genomic profiling (CGP) panel delivers results within 7 to 10 business days, addressing one of the most significant operational bottlenecks facing pharmaceutical sponsors and CROs conducting cancer clinical trials in the European Union.
The company announced that Luminos® Comprehensive is validated as an IVDR-compliant laboratory-developed test (LDT) and deployed in-house at Discovery Life Sciences’ Kassel, Germany genomic facility under Health Institution status in accordance with Article 5(5) of the EU In Vitro Diagnostic Regulation (IVDR). The launch comes ahead of ASCO 2026, where Discovery Life Sciences plans to showcase the platform to global pharmaceutical sponsors and oncology researchers.
Industry experts believe the platform could significantly improve enrollment speed, biomarker stratification, and operational efficiency for oncology trials conducted across European clinical sites, where genomic testing delays have increasingly impacted study timelines and patient recruitment.
Luminos Addresses Growing IVDR Compliance Challenges
The European Union’s IVDR framework has created major compliance and operational hurdles for pharmaceutical companies running prospective oncology studies. Many sponsors have struggled to access in-house IVDR-compliant genomic testing solutions capable of supporting enrollment screening while meeting strict European regulatory requirements.
Advertisement
According to Discovery Life Sciences, most reference laboratories either lack Health Institution status, rely on narrow targeted panels instead of broad genomic profiling, or require three to four weeks to return results. Such delays can significantly slow patient enrollment and increase overall clinical trial costs.
Luminos® Comprehensive was developed specifically to close this compliance and operational gap. The platform supports prospective clinical use, biomarker stratification, and enrollment screening without requiring third-party laboratory routing or additional performance-study overhead. Discovery Life Sciences noted that avoiding separate performance studies could potentially save sponsors up to six months during oncology trial startup activities.
The company emphasized that its Kassel facility was purpose-built to operate under IVDR Health Institution status from inception rather than retrofitted from a conventional research laboratory model, providing pharmaceutical companies with a more scalable and compliant genomic testing environment.
Comprehensive Genomic Profiling Supports Precision Oncology
The Luminos® Comprehensive panel analyzes 164 clinically relevant genes associated with oncology treatment response, biomarker discovery, and emerging therapeutic targets. The assay includes established biomarkers such as EGFR, KRAS, BRAF, PIK3CA, HER2, and TP53, along with next-generation targets involving DNA damage repair, mismatch repair pathways, and kinase signaling networks.
Researchers can use the platform for patient stratification, companion diagnostic development, biomarker analysis, and precision medicine initiatives within oncology clinical programs. Discovery Life Sciences stated that the rapid turnaround time may provide measurable advantages in patient cycle times, site activation speed, and enrollment velocity for multi-site cancer studies.
Healthcare experts increasingly view comprehensive genomic profiling as essential for modern oncology research because targeted therapies and immunotherapies depend heavily on accurate molecular characterization of tumors. Faster genomic data availability may help clinicians identify eligible patients more efficiently while accelerating therapeutic decision-making.
The company also confirmed that additional omics and liquid biopsy capabilities are already under development through its broader Luminos® platform expansion strategy.
AI, Genomics, and Precision Medicine Continue Converging
Discovery Life Sciences highlighted that the launch reflects growing demand for scalable genomic infrastructure capable of supporting AI-driven oncology research, advanced biomarker discovery, and precision medicine development. The company currently partners with more than 1,150 biopharma organizations, including all top 25 global pharmaceutical companies and leading companion diagnostic manufacturers.
Industry analysts believe the convergence of genomics, AI, and regulatory-compliant molecular diagnostics is rapidly transforming global oncology research. As pharmaceutical companies continue developing highly targeted cancer therapies, demand for fast, compliant, and high-throughput genomic testing solutions is expected to rise substantially across Europe and other regulated healthcare markets.
Discovery Life Sciences also announced that Luminos® Liquid, a cfDNA/cfRNA liquid biopsy panel validated under IVDR Health Institution status, is expected to launch in Fall 2026, further expanding the company’s precision oncology capabilities.
Source: Discovery Life Sciences press release
